SEC 13F Intelligence

Propel Bio Management, LLC / AKRO

Propel Bio Management, LLC’s Akero Therapeutics Inc Com Position

Does Propel Bio Management, LLC own Akero Therapeutics Inc Com (AKRO)? Not currently — the last reported position was 228.9K shares worth $11M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$11M
Q3 2025
Shares
228.9K
% of Portfolio
+10.88%
Quarters Held
8
position exited

Position History AKRO

Reported value by quarter
Q4 ’23: $2MQ4 ’23Q1 ’24: $8MQ1 ’24Q2 ’24: $8MQ2 ’24Q3 ’24: $10MQ3 ’24Q4 ’24: $10MQ4 ’24Q1 ’25: $9MQ1 ’25Q2 ’25: $12MQ2 ’25Q3 ’25: $11MQ3 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2025228.9K$11M+10.88%
Q2 2025228.9K$12M+14.82%
Q1 2025228.9K$9M+10.76%
Q4 2024343.7K$10M+9.50%
Q3 2024343.7K$10M+5.72%
Q2 2024327.8K$8M+4.99%
Q1 2024327.8K$8M+4.82%
Q4 2023100.1K$2M+1.94%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of AKRO.